Big Pharma's Patent Headache
Women with brittle bones could be in for a bit of a windfall come Feb. 6. That's when Merck's (MRK) Fosamax, the market-leading osteoporosis drug, comes off patent and patients can start buying generic versions. If history holds, prices for the generic medication, called alendronate, should run 40% to 60% less than the $90 a month Fosamax tends to cost.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.